Longitudinal Evaluation and Real-world Evidence of NT201

LONG RUN: LONGitudinal Evaluation and Real-world Evidence of Uniquely Purified incobotulinumtoxinA (Xeomin) in Treatment Naïve Participants

This study is to collect long-term real-world evidence data from clinics in several countries in order to obtain an improved understanding of the safety and effectiveness of incobotulinumtoxinA in botulinum neurotoxin type A (BoNT-A) treatment naïve participants.

Inclusion Criteria:

• 18 years of age or older.
• Planning treatment with incobotulinumtoxinA.

Exclusion Criteria:

• Any contraindication to treatment with incobotulinumtoxinA or any other neurotoxins.
• Currently pregnant, breastfeeding, or intending to become pregnant during study participation.
• Known hypersensitivity to incobotulinumtoxinA or any of its formulation ingredients.
• Any infection and/or inflammation at the planned injection points.
• Previous treatment with any botulinum toxin products for any aesthetic or therapeutic indications.